Some investors asked questions on the investor interactive platform: Hello Secretary of the Board of Directors, please consult the following questionsbestarcadegamesofalltime:1. Have your company obtained terbutaline sulfate solution for nebulized inhalation and other drugs on the market? What is the market share? 2. The country vigorously develops synthetic biotechnology. Does the company have synthetic biological products or technology reserves? thank

Huluwa (605199.SH) stated on the investor interactive platform on May 14 that the company was approved and issued by the State Food and Drug Administration on April 23, 2024bestarcadegamesofalltimeThe "Drug Registration Certificate" for terbutaline sulfate solution for nebulized inhalation has not yet been sold. There are currently no synthetic biological products or technical reserves.

(Article source: Daily Economic News)